Evaluation of seat performance criteria for rear‐end impact testing BioRID II and insurance data
Evaluation of seat performance criteria for rear‐end impact testing BioRID II and insurance data
复制标题
追尾碰撞测试 BioRID II 的座椅性能标准评估和保险数据
DOI：
--
复制
发表时间：
2011
期刊：
影响因子：
--
通讯作者：
A. Kullgren
中科院分区：
文献类型：
--
作者：
J. Davidsson;A. Kullgren
BioRID建议用于立法后端冲击座椅测试。然而，缺乏推荐的损伤标准；生物力学数据是有限的，限制了对所提出标准的任何评估。本研究旨在通过比较BioRID II的雪橇试验数据与现实生活中的事故数据来解决这些局限性。结果将评估完整雪橇测试方法的损伤可预测性，包括性能标准、通用加速脉冲的使用和BioRID等。根据Folksam提供的数据，计算了17组类似座椅设计的真实生活伤害风险。保险件数从每组150件到1136件不等。计算回归系数。使用了两种类型的伤害风险：导致记录的持续时间超过一个月的症状和被归类为导致永久性医疗损伤的由于后端撞击的后果。将这些风险与BioRID II以16 km/h脉冲进行的滑橇试验的参数值进行了比较。NIC，最大后枕髁相对T1 - x位移和L1 - x -加速度最好地预测发生永久性医疗损伤的风险和超过一个月的症状，假设乘员在后端撞击后出现初始症状。
The BioRID is recommended for legislative rear‐end impact seat tests. Recommended injury criteria are, however, lacking; biomechanical data are limited and confines any evaluation of proposed criteria. This study aimed at addressing these limitations by comparing BioRID II data from sled tests with real‐life accident data. Results will evaluate injury predictability of the complete sled test method, which includes performance criteria, the use of a generic acceleration pulse, and the BioRID, etc. Real‐life injury risk was calculated for 17 groups of similar seat designs from data provided by Folksam. The number of insurance cases range from 150 to 1136 per group. Regression coefficients were calculated. Two types of injury risks were used: those leading to documented symptoms of more than one month’s duration and those classified as leading to permanent medical impairment as a consequence of a rear‐end impact. These risks were compared to parameter values from sled tests performed with a BioRID II at 16 km/h pulses. NIC, the maximum rearward Occipital Condyle relative T1 x‐displacements and L1 x‐acceleration best predicted the risk of developing permanent medical impairment and symptoms of more than one month, given the occupant had initial symptoms following a rear‐end impact.